Members of a new class of antivirals are being tested in U.S. clinical trials, and one has gained approval in Japan, but how ...
A new study headed by teams at the Wellcome Sanger Institute, EMBL’s European Bioinformatics Institute (EMBL-EBI), and Open Targets has indicated how mutations that cause cancer drug resistance fall ...
An update from China’s NMPA clarifying registration requirements and classification methods for drug-device combination products has been welcomed by industry as the regulator seeks to keep pace with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback